Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients
The Pharmacogenomics Journal · 2024-08 · 24 (4)
DOI: 10.1038/s41397-024-00341-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Pharmacogenomics Journal, online erschienen am 21.06.2024. Verfasst von Juliana Salazar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medical Oncology Laboratory, Institut de Recerca Biomèdica Sant Pau (IIB-Sant Pau), Barcelona, Spain. Hauptthemen laut MEDLINE: Crohn Disease, Pyrophosphatases, Azathioprine, Methyltransferases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Thiopurines, an effective therapy for Crohn's disease (CD), often lead to adverse events (AEs). Gene polymorphisms affecting thiopurine metabolism may predict AEs. This retrospective study in CD patients (n = 114) with TPMT activity > 5 Units/Red Blood Cells analyzed TPMT (c.238 G > C, c.460 G > A, c.719 A > G), ITPA (c.94 C > A, IVS2 + 21 A > C), and NUDT15 (c.415 C > T) polymorphisms. All patients received azathioprine (median dose 2.2 mg/kg) with 41.2% experiencing AEs, mainly myelotoxicity (28.1%). No NUDT15 polymorphisms were found, 7% had TPMT, and 31.6% had ITPA polymorphisms. AEs led to therapy modifications in 41.2% of patients. Multivariate analysis identified advanced age (OR 1.046, p = 0.007) and ITPA IVS2 + 21 A > C (OR 3.622, p = 0.015) as independent predictors of AEs. IVS2 + 21 A > C was also associated with myelotoxicity (OR 2.863, p = 0.021). These findings suggest that ITPA IVS2 + 21 A > C polymorphism and advanced age predict AEs during thiopurine therapy for CD with intermediate-normal TPMT activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Medical Oncology Laboratory, Institut de Recerca Biomèdica Sant Pau (IIB-Sant Pau), Barcelona, Spain.
- Pharmacy Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
- CIBERER U-705, Barcelona, Spain.
- IBD Unit Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Institut de Recerca Biomèdica Sant Pau (IIB-Sant Pau), Barcelona, Spain.
- Hematology Department, Fundació Althaia, Manresa, Barcelona, Spain.
ORCID-Profile: Juliana Salazar, Pau Riera, Albert Altès, Miguel Martínez, Antonio Giordano
Zitieren
APA
Salazar, J., Riera, P., Gordillo, J., Altès, A., Martínez, M., Serès, M., Llaó, J., Giordano, A., & Garcia-Planella, E. (2024). Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients. The Pharmacogenomics Journal, 24(4). https://doi.org/10.1038/s41397-024-00341-2
Vancouver
Salazar J, Riera P, Gordillo J, Altès A, Martínez M, Serès M, et al. Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients. The Pharmacogenomics Journal. 2024;24(4). doi:10.1038/s41397-024-00341-2
BibTeX
@article{Salazar2024,
author = {Salazar, Juliana and Riera, Pau and Gordillo, Jordi and Altès, Albert and Martínez, Miguel and Serès, Montserrat and Llaó, Jordina and Giordano, Antonio and Garcia-Planella, Esther},
title = {Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients},
journal = {The Pharmacogenomics Journal},
year = {2024},
volume = {24},
number = {4},
doi = {10.1038/s41397-024-00341-2}
}
EUVIMED